Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (97).”
MethodType 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationChamberlain, J. J., Rhinehart, A. S., Shaefer, C. F., & Neuman, A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3016 · Cited by 631
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia
Umpierrez, G., & Korytkowski, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.15 · Cited by 563
Chiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 509
“Suspending basal insulin delivery for low sensor glucose levels has been shown to markedly reduce hypoglycemia without worsening glycemia (52).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Amiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications
Frier, B. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.170 · Cited by 481
Hayati Rezvan, P., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 459
“In three articles [40,47,84], logistic regression method and in two articles [39,113], linear regression method were stated as a imputation method for handling missing data.”
BackgroundMethodCappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
“Just to mention a few, recent research proved CGM sensors to be effective for patients with frequent hypoglycemic events [7], sensor augmented pumps [50], and gestational diabetes [47], treated with either continuous subcutaneous insulin infusion (CSII) or a multiple daily injection (MDI) insulin regimen.”
Background8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
“This simple and straightforward algorithm was shown to be very effective in reducing the risk of nocturnal hypoglycemia 88–91 : there was a 38% reduction in the AUC below 70 mg/dL for subjects using the threshold sus-pend.”
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Machine Learning and the Profession of Medicine
Darcy, A. M., Louie, A. K., & Roberts, L. W. (2016) · JAMA · doi:10.1001/jama.2015.18421 · Cited by 434
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citation6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
14. Children and Adolescents: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s014 · Cited by 367
Continuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Self-citationAssessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M. J., Pillay, K., de Beaufort, C., Craig, M. E., Hanas, R., Acerini, C. L., & Maahs, D. M. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12190 · Cited by 316
“is below a specified range or with rapid rate of fall of glucose (63, 64, 87).”
Insulin delivery methods: Past, present and future
Shah, R., Shah, V., Patel, M., & Maahs, D. (2016) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.176456 · Cited by 287
“[43] In clinical trials, TS reduced the severity of nocturnal hypoglycemia by 30-40% and reduced the duration of severe hypoglycemia without altering A1c values.[44,45] Recently, the TS system has been approved by US Food and Drug Administration (FDA) after having been approved in 2009 in other countries.”
New closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 270
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Self-citation13. Children and Adolescents: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s013 · Cited by 267
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 271
“The Automation to Simulate Pancreatic Insulin Response (ASPIRE) trial of 247patientswith type1diabetes anddocumented nocturnal hypoglycemia showed that sensor-augmented insulin pump therapy with a low glucose suspend function significantly reduced nocturnal hypoglycemia over 3 months without increasing A1C levels (25).”
Background9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
“One study in adults with documented nocturnal hypoglycemia randomly assigned 247 patients to an SIP or an SAP that could stop insulin delivery for up to 2 hours (116).”
MethodSelf-citationForlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
“8% fewer nocturnal hypoglycemia events using a threshold suspend system compared with sensor-augmented pump (SAP) therapy (10).”
MethodAdvances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
Self-citationLittle, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Assessing Sensor Accuracy for Non-Adjunct Use of Continuous Glucose Monitoring
Kovatchev, B. P., Patek, S. D., Ortiz, E. A., & Breton, M. D. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0272 · Cited by 234
“38 Predictive algorithms bring the CGM information processing to a higher level, 39 and closed-loop control, known as the artificial pancreas, offers the ultimate retrieval of CGM information via complex algorithms, typically based on elaborate models of the human glucose metabolism.”
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Abraham, M. B., Jones, T. W., Naranjo, D., Karges, B., Oduwole, A., Tauschmann, M., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12698 · Cited by 226
7. Approaches to Glycemic Treatment
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225
13. Children and Adolescents: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s013 · Cited by 223
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
“The sensor-augmented pump is further enhanced via ‘lowglucose suspend’ and ‘predictive low-glucose suspend’ features [12, 13, 53].”
BackgroundMethod14. Children and Adolescents: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s014 · Cited by 200
Haidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 215
Minimizing Hypoglycemia in Diabetes
International Hypoglycaemia Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0279 · Cited by 209
Hovorka, R., Elleri, D., Thabit, H., Allen, J. M., Leelarathna, L., El-Khairi, R., Kumareswaran, K., Caldwell, K., Calhoun, P., Kollman, C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2644 · Cited by 214
Plasmonic silver nanoshells for drug and metabolite detection
Huang, L., Wan, J., Wei, X., Liu, Y., Huang, J., Sun, X., Zhang, R., Gurav, D. D., Vedarethinam, V., Li, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00220-4 · Cited by 210
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
“nocturnal hypoglycemia, without increasing A1C levels for those over 16 years of age (19).”
Background13. Children and Adolescents: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s013 · Cited by 200
12. Children and Adolescents: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s012 · Cited by 194
Pickup, J. C., Ford Holloway, M., & Samsi, K. (2015) · Diabetes Care · doi:10.2337/dc14-1855 · Cited by 189
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
“Glycemic variability, measured as sensor glucose SD and coefficient of variation (CV) in the STAR3 group was assessed.171 Those with HbA1c 8% in the SAP group were found to have lower sensor glucose SD and CV than those in the control group, suggesting that glycemic excursions may be reduced with use of this technolog…”
BackgroundMethodInfluentialFonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
“Moreover, no severe hypoglycemic events occurred in the threshold suspend group compared with 4 events in the control group (15).”
BackgroundMethodInfluentialSelf-citationHypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 230
7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s010 · Cited by 181
14. Children and Adolescents: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s014 · Cited by 165
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Jovanovič, L., Lane, W. S., Raskin, P., Tamborlane, W. V., et al. (2014) · Endocrine Practice · doi:10.4158/ep14145.ps · Cited by 180
“The use of this device has been shown to reduce nocturnal hypoglycemia (19).”
BackgroundSelf-citationLind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 192
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Nimri, R., Muller, I., Atlas, E., Miller, S., Fogel, A., Bratina, N., Kordonouri, O., Battelino, T., Danne, T., & Phillip, M. (2014) · Diabetes Care · doi:10.2337/dc14-0835 · Cited by 169
The artificial pancreas: current status and future prospects in the management of diabetes
Peyser, T., Dassau, E., Breton, M., & Skyler, J. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12431 · Cited by 169
Pozzilli, P., Battelino, T., Danne, T., Hovorka, R., Jarosz‐Chobot, P., & Renard, E. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2653 · Cited by 160
Technology in the management of type 1 diabetes mellitus — current status and future prospects
Tauschmann, M., & Hovorka, R. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0044-y · Cited by 183
A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes
Maahs, D. M., Calhoun, P., Buckingham, B. A., Chase, H. P., Hramiak, I., Lum, J., Cameron, F., Bequette, B. W., Aye, T., Paul, T., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2159 · Cited by 160
Self-citationBally, L., Thabit, H., Kojzar, H., Mader, J. K., Qerimi-Hyseni, J., Hartnell, S., Tauschmann, M., Allen, J. M., Wilinska, M. E., Pieber, T. R., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30001-3 · Cited by 162
Battelino, T., Nimri, R., Dovč, K., Phillip, M., & Bratina, N. (2017) · Diabetes Care · doi:10.2337/dc16-2584 · Cited by 157
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
“Additionally, glucose levels remained stable even 2 h post nocturnal insulin suspension.(145)”
BackgroundMethodThabit, H., Lubina-Solomon, A., Stadler, M., Leelarathna, L., Walkinshaw, E., Pernet, A., Allen, J. M., Iqbal, A., Choudhary, P., Kumareswaran, K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70114-7 · Cited by 162
Berget, C., Messer, L. H., & Forlenza, G. P. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0091 · Cited by 175
“Studies using LGS have demonstrated a 40–50% reduction in hypoglycemia (<70 mg/dL), without an increase in A1C or mean sensor glucose values compared to SAP therapy alone (40,41).”
MethodClosed-Loop Insulin Delivery Systems: Past, Present, and Future Directions
Templer, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.919942 · Cited by 182
“A recent randomized trial of hybrid closed-loop therapy in children aged 1 to 7 demonstrated significant improvements in time in range, HbA1c, and mean glucose level compared to sensoraugmented pump therapy, without a significant difference in total daily insulin dose (75).”
BackgroundInfluentialHeinemann, L., Fleming, G. A., Petrie, J. R., Holl, R. W., Bergenstal, R. M., & Peters, A. L. (2015) · Diabetes Care · doi:10.2337/dc15-0168 · Cited by 143
Self-citationImproving the clinical value and utility of CGM systems: issues and recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetologia · doi:10.1007/s00125-017-4463-4 · Cited by 148
Self-citationAbraham, M. B., Nicholas, J. A., Smith, G. J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., & on behalf of the PLGM Study Group (2017) · Diabetes Care · doi:10.2337/dc17-1604 · Cited by 144
Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R. H., Wadwa, R. P., Wilson, D. M., Ly, T. T., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3053 · Cited by 148
Self-citationAn Overview of Insulin Pumps and Glucose Sensors for the Generalist
McAdams, B., & Rizvi, A. A. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5010005 · Cited by 158
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135
Self-citationLeelarathna, L., Dellweg, S., Mader, J. K., Allen, J. M., Benesch, C., Doll, W., Ellmerer, M., Hartnell, S., Heinemann, L., Kojzar, H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2911 · Cited by 140
Tauschmann, M., Allen, J. M., Wilinska, M. E., Thabit, H., Stewart, Z., Cheng, P., Kollman, C., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2015) · Diabetes Care · doi:10.2337/dc15-2078 · Cited by 141
“The advent of novel technologies such as threshold-suspend insulin pump therapy (15) and more recently predictive low glucose suspend (16) may reduce hypoglycemia risk.”
BackgroundBiester, T., Kordonouri, O., Holder, M., Remus, K., Kieninger‐Baum, D., Wadien, T., & Danne, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0349 · Cited by 133
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.